evipedia.ai
← Back

L-Tyrosine for Health & Longevity

Evidence Review created on 08/27/2026 using AI4L / Opus 5

Also known as: Tyrosine, N-Acetyl-L-Tyrosine, NALT, 4-Hydroxyphenylalanine, Tyr

Motivation

L-Tyrosine, usually sold simply as tyrosine, is an amino acid — one of the building blocks of protein. The body also uses it as raw material for dopamine, noradrenaline and adrenaline, the chemical messengers behind alertness and the stress response, and for thyroid hormones and skin pigment. The body can make it from protein in food, so shortages are rare.

Interest in taking extra tyrosine grew out of military and polar research, where people had to stay sharp while cold, short of oxygen or sleep-deprived. The reasoning is that heavy, sustained stress drains these messengers faster than the brain replaces them, and that adding raw material helps refill the supply. A newer line of work asks the opposite question: whether people who naturally carry more tyrosine in the blood tend to live shorter lives.

This review examines what the evidence shows about supplemental L-Tyrosine for health and longevity: where it changes how people perform and where it does not, what is known about its safety and its interactions, and how it is used in practice.

Benefits - Risks - Protocol - Conclusion

High-level overviews of L-Tyrosine from expert platforms and from narrative scientific reviews that treat the compound in depth.

Note on priority-expert coverage: content from two priority experts was not included. Peter Attia and Chris Kresser have no article or episode devoted to tyrosine; the compound appears only in passing within broader dopamine and thyroid material. Rhonda Patrick does address supplemental tyrosine in a FoundMyFitness listener question, but that segment sits behind a members-only paywall and could not be read or verified, so it was not listed.

Grokipedia

  • Tyrosine

    Grokipedia’s dedicated article covers tyrosine’s chemistry, biosynthesis from phenylalanine, its role as precursor to catecholamines (dopamine and related stress hormones), thyroid hormones and melanin, and the inherited disorders involved.

Examine

  • L-Tyrosine

    Examine’s primary L-Tyrosine page grades outcomes across 24 trials, gives per-kilogram dose ranges, and carries a structured safety database covering side effects, interactions, pregnancy and precautions.

ConsumerLab

  • L-Tyrosine: Health Effects and Safety

    ConsumerLab’s dedicated article reviews tyrosine for stress, phenylketonuria (an inherited inability to process phenylalanine), depression and attention deficit; full benefit and safety detail requires membership.

Systematic Reviews

Systematic reviews and meta-analyses that bear on L-Tyrosine’s claimed cognitive and performance benefits and on the metabolic risk signal attached to elevated tyrosine.

Mechanism of Action

L-Tyrosine is the substrate at the head of the catecholamine pathway — the assembly line producing dopamine, noradrenaline and adrenaline. Tyrosine hydroxylase (the enzyme that adds a hydroxyl group to tyrosine, and the chain’s slowest step) converts it to L-DOPA (levodopa, the Parkinson’s drug); DOPA decarboxylase then yields dopamine, which dopamine beta-hydroxylase converts to noradrenaline and, in the adrenal glands, to adrenaline. Tyrosine is also iodinated in the thyroid to build thyroxine and triiodothyronine, and oxidised by tyrosinase to build melanin.

To reach the brain, tyrosine must cross the blood–brain barrier on LAT1 (the large neutral amino acid transporter, a shared shuttle that also carries phenylalanine, tryptophan and the branched-chain amino acids). Because these compete for the same seats, the ratio of tyrosine to its competitors — not the absolute dose — governs brain uptake. It has no receptor selectivity: it is a substrate distributed to all tissues, peaking in plasma at 90–120 minutes and clearing with a two-to-three-hour half-life, dismantled in the liver by tyrosine aminotransferase and 4-hydroxyphenylpyruvate dioxygenase rather than by drug-metabolising enzymes.

Two mechanistic readings compete. The depletion–repletion account, set out by Jongkees et al., holds that tyrosine hydroxylase is normally saturated, so extra substrate does nothing at rest; only when sustained firing depletes stores does supply become limiting. Fernstrom & Fernstrom read it more permissively — added tyrosine raises catecholamine synthesis in any actively firing neuron — but note that tyrosine inhibits its own hydroxylase at high concentrations, predicting that larger doses blunt the effect.

Historical Context & Evolution

Tyrosine was isolated from casein by Justus von Liebig in 1846 and was, for a century, of purely nutritional interest — a non-essential amino acid the body makes from phenylalanine. Its clinical debut came through inherited metabolic disease: children with phenylketonuria (an inherited inability to break down phenylalanine) cannot make tyrosine normally, and from the 1950s onward tyrosine supplementation was proposed to fill that gap.

The performance era began in the 1970s at the Massachusetts Institute of Technology, where Richard Wurtman’s group showed that dietary precursors could alter brain neurotransmitter synthesis. That work motivated trials of tyrosine for depression. Gelenberg et al. ran 65 outpatients on tyrosine, imipramine or placebo for four weeks: tyrosine raised MHPG (a breakdown product of noradrenaline), confirming it reached its target, yet produced no antidepressant effect. The finding is often described as a failure, but read directly it is informative — it separated biochemical engagement from clinical benefit.

Military laboratories then reframed the question. Banderet & Lieberman exposed volunteers to cold and low oxygen for 4.5 hours and found tyrosine reduced symptoms and performance loss specifically in those who reacted strongly to the stressor. That conditional result — benefit only under load — became the field’s organising idea and remains contested rather than settled, with newer biobank work now pointing in a different direction entirely.

Expected Benefits

Framing note: the audience for this section is a proactive adult already optimising sleep, training and nutrition. For that reader the relevant question is not whether tyrosine helps the average person, but whether it does anything on a good day — and the literature’s clearest signal is that it does not.

High 🟩 🟩 🟩

Preserved Cognitive Performance During Acute Environmental and Sleep Stress

Under an imposed stressor, tyrosine protects working memory, vigilance and psychomotor tracking. The proposed mechanism is repletion of catecholamines depleted by sustained stress signalling. The evidence is a consistent series of small randomised controlled trials (RCTs — studies assigning participants at random to the supplement or a dummy) across four stressors: cold plus low oxygen in Banderet & Lieberman, loud noise in Deijen & Orlebeke, cold in Shurtleff et al., and extended wakefulness in Neri et al.. Trials are small and task batteries differ.

Magnitude: Benefit appears only when a stressor is present and is short-lived: 150 mg/kg cut lapse probability on a high-event-rate vigilance task and blunted psychomotor decline for roughly three hours during 24 hours of wakefulness, and 2 g daily improved memory and tracking scores by the sixth day of a combat course. Because the trials enrol 8–21 people each and use non-overlapping task batteries, the literature reports no pooled outcome figure.

Medium 🟩 🟩

Better Core Temperature Maintenance During Cold Exposure in Older Adults

Ageing blunts the reflex narrowing of skin blood vessels that conserves heat, leaving older adults prone to excess heat loss. Tyrosine supplies the catecholamine substrate for that reflex. In a randomised double-blind trial by Lang et al., 150 mg/kg restored the cold response in adults aged around 72 to the level seen in adults aged around 25. An earlier trial from the same laboratory found the same augmented vessel response, so the finding rests on one group’s work.

Magnitude: Over 90 minutes of whole-body cooling, cutaneous vascular conductance (a measure of skin blood flow) rose 32.7% from baseline on tyrosine versus 14.4% on placebo, and the fall in oesophageal (core) temperature was 0.07 °C versus 0.29 °C.

Lower Blood Pressure Under Acute Psychological Stress

Blood pressure reactivity to stress is a validated cardiovascular surrogate, and two trials recorded a fall on tyrosine. Deijen & Orlebeke found lower diastolic pressure 15 minutes after 100 mg/kg under 90-decibel noise, an effect gone by one hour; Deijen et al. found lower systolic pressure in cadets after six days of 2 g daily. Each parameter was seen once, in a secondary analysis, in fewer than 25 participants — this is a single-trial-grade finding per endpoint.

Magnitude: The direction is consistently downward and the effect holds only while an acute stressor is applied, disappearing within an hour in the noise-stress trial. Neither trial designated blood pressure as a primary endpoint, so the literature reports no outcome figure for it.

Low 🟩

Enhanced Inhibitory Control Without an Imposed Stressor ⚠️ Conflicted

Tyrosine may sharpen response inhibition in rested adults via prefrontal dopamine. A double-blind crossover by Colzato et al. improved stop-signal performance at 2 g, but the same group’s genotype-stratified trial confined the gain to T/T carriers of DRD2 (dopamine D2 receptor gene). Net reading: the signal is narrow and unreplicated.

Magnitude: The direction is faster stopping with go-response speed unchanged, holding at a single 2 g dose in rested young adults. Because the two trials use different tasks and one splits by genotype, the literature reports no pooled outcome figure.

Endurance Capacity When Mental Fatigue Precedes Exercise ⚠️ Conflicted

Tyrosine may defend central drive when the brain is already fatigued. Solon-Júnior et al. found a gain in 12 cyclists after a cognitive task, while Tumilty et al. and the pooled meta-analysis found nothing. Net reading: any benefit is confined to prior mental fatigue and remains unproven.

Magnitude: Time to exhaustion rose about 16% (460 s versus 399 s) in mentally fatigued cyclists; pooled endurance effect sizes (a standardised measure of how large a difference is) were 0.02 and −0.04, both non-significant — indistinguishable from no effect.

Mood Improvement in Depression ⚠️ Conflicted

Early open reports claimed rapid remission in dopamine-dependent depression. The one adequately powered trial, Gelenberg et al., randomised 65 outpatients to tyrosine, imipramine or placebo and found no antidepressant signal despite biochemical engagement. Net reading: tyrosine is not an antidepressant.

Magnitude: Not quantified in available studies. The single controlled trial reported no difference from placebo on depression ratings and published no effect estimate; the positive claims come from uncontrolled case series.

Symptom Reduction in Attention-Deficit/Hyperactivity Disorder

An open trial in adults with residual attention deficit disorder by Reimherr et al. reported early improvement that faded within weeks despite continued dosing, consistent with tolerance. No placebo-controlled replication exists.

Magnitude: Improvement appeared in the first two weeks and was lost by eight weeks at 150 mg/kg daily; because the trial was uncontrolled, the literature reports no outcome figure.

Speculative 🟨

Support of Thyroid Hormone Production

Tyrosine is the backbone iodine attaches to when the thyroid builds hormones, which is why it appears in thyroid formulas. No trial shows that supplementing a replete person raises hormone output; the basis is mechanistic.

Restoration of Tyrosine Status on Phenylalanine-Restricted Diets

In phenylketonuria, supplementation reliably raises blood tyrosine. Blood tyrosine is an unvalidated marker: the Cochrane review found no accompanying gain in intelligence, neuropsychological performance, growth or quality of life.

Benefit-Modifying Factors

  • DRD2 genotype: C957T is a functional variant of the dopamine D2 receptor gene. In a randomised trial by Colzato et al., T/T homozygotes — with presumed lower brain dopamine — gained on working memory and inhibition, while C/C carriers did not.

  • COMT genotype: COMT (the enzyme that clears dopamine from the prefrontal cortex) varies functionally between people. Fast-clearing Val/Val carriers hold less prefrontal dopamine at baseline and are the group most plausibly repleted by added substrate, though no tyrosine trial has stratified by COMT directly.

  • Baseline plasma tyrosine and competing amino acids: Brain uptake tracks the ratio of tyrosine to phenylalanine, tryptophan and branched-chain amino acids, not the dose. A high-protein meal raises all competitors together and can neutralise a supplemental dose entirely.

  • Sex: No trial has reported a sex difference in the cognitive response, and most enrolled men only. Sex differences appear instead in the longevity signal, where Zhao et al. found the tyrosine–lifespan association in men but not clearly in women.

  • Pre-existing conditions: Benefit is largest where catecholamine supply is genuinely constrained — phenylketonuria, dopamine-depleting stress, and the blunted vascular reflexes of ageing. In metabolically healthy, unstressed people the same trials show no effect.

  • Age: Older adults gain most on thermoregulation but are the group in which higher doses impaired working memory in van de Rest et al.. Age therefore shifts which benefit is achievable and narrows the useful dose window.

Potential Risks & Side Effects

Framing note: for a proactive adult the practical risk is not acute toxicity — short-course tyrosine is well tolerated — but the chronic-exposure question raised by the mortality and metabolic literature, which no supplement trial has been designed to answer.

High 🟥 🟥 🟥

No risk reaches High: the controlled human evidence consists of single-dose or short crossover trials of fewer than 100 participants each, none of which documents a replicated adverse event, and the long-term safety evidence is rodent feeding studies and isolated case reports rather than repeated human trials.

Medium 🟥 🟥

Increased Anger and Irritability Under Severe Stress

In the largest controlled stress study of tyrosine, Lieberman et al. gave 300 mg/kg to military personnel before mock interrogations during survival training. Tyrosine left most mood and physiological measures untouched but raised self-rated anger. The proposed mechanism is heightened noradrenaline signalling. The authors read the shift as possibly adaptive in a survival setting; outside that setting it is an unwanted effect, and it is the only mood change any adequately sized trial has isolated.

Magnitude: The direction is upward and it holds only while the severe stressor is applied, appearing on the Profile of Mood States immediately after the second mock interrogation and the following morning (p = 0.002, meaning a result this large would rarely arise by chance) in 72 participants at 300 mg/kg split into two doses. The trial charted the anger subscale rather than tabulating it, so the literature reports no outcome figure.

Impaired Working Memory in Older Adults at Higher Doses

Tyrosine’s effect on cognition is not a straight line. In a double-blind crossover trial, van de Rest et al. gave adults aged 60–75 single doses of 100, 150 or 200 mg/kg and found that load-dependent working-memory performance fell as the dose rose, with the worst performance in those whose plasma tyrosine rose most. Older adults reached far higher plasma levels than young adults on an identical dose, consistent with slower clearance. This is a single trial in 17 people.

Magnitude: The direction is downward with rising dose and it holds only at the hardest working-memory load, where accuracy fell at 150 and 200 mg/kg relative to 100 mg/kg (p = 0.048) and tracked the size of the individual plasma tyrosine response (p = 0.035), in adults aged 60–75. Accuracy was plotted rather than reported as a score change, so the literature reports no outcome figure.

Higher Circulating Tyrosine Tracks With Shorter Lifespan and Metabolic Disease

Elevated circulating tyrosine is a consistent adverse marker. The meta-analysis by Guasch-Ferré et al. pooled eight prospective cohorts; Dai et al. followed 1,238 older adults for nine years; and Zhao et al. added Mendelian randomization (using inherited gene variants as a natural experiment to test causality) in 272,475 UK Biobank participants. The gap is inferential: no study measured supplement users, so it is unknown whether an intermittent dose reproduces a chronically elevated level.

Magnitude: Risk of type 2 diabetes rose 36% per standard-deviation increase in tyrosine (relative risk 1.36 — how many times the risk of the unexposed; 95% confidence interval, the range the true value most likely lies in, 1.19–1.55). All-cause mortality roughly doubled in the top versus bottom quarter of the tyrosine range (hazard ratio 2.18, the same kind of multiplier applied to the rate of death, 1.01–4.71), and genetically predicted higher tyrosine cost men 0.91 years of life.

Low 🟥

Gastrointestinal Upset, Nausea, Headache and Fatigue

At doses above roughly 100 mg/kg taken at once, nausea, heartburn, headache and fatigue are the commonly described complaints. Reporting is unsystematic: trials such as Neri et al. record adverse events only narratively, and reference sources note that no thorough human safety analysis exists.

Magnitude: Not quantified in available studies. No trial was powered or designed to collect standardised tolerability data, so incidence rates for these symptoms have never been established.

Reduced Levodopa Effect in Parkinson’s Disease

Levodopa competes with tyrosine for LAT1 transport across the gut wall and the blood–brain barrier. Protein loads blunt levodopa response for this reason, and a tyrosine bolus is the same problem concentrated. The human data are indirect, from dietary protein rather than supplements — see this systematic review.

Magnitude: The direction is a reduced or delayed levodopa response, and it holds when the amino acid load and the dose coincide in time; protein redistribution diets exploit the same competition. No trial has measured a tyrosine-specific figure.

Speculative 🟨

Additive Thyroid Stimulation in Thyroid Disease

Tyrosine is the scaffold for thyroid hormones, so supplementation is theorised to worsen an overactive thyroid. No human case has been reported; the basis is mechanism plus rodent work in which thyroxine aggravated tyrosine toxicity.

Fuelling of Melanoma

Melanoma cells make melanin from tyrosine, and restricting it suppressed tumour metastasis in rodent models. Whether supplementation does the reverse in people is untested; the basis is animal work only.

Blood, Liver and Kidney Changes on Extreme Chronic Intake

A 13-week rat study at roughly 320 mg/kg human-equivalent daily produced adverse blood, liver and kidney findings. Very high animal intakes also caused eye disease, hair loss and shortened lifespan. No human parallel exists.

Delayed Sleep Onset After Late Dosing

Raising catecholamine tone in the second half of the day plausibly postpones sleep onset, and the effect would compound with caffeine. No trial has measured sleep after tyrosine; the basis is mechanism only.

Risk-Modifying Factors

  • Genotype: DRD2 C/C homozygotes, who carry presumed higher brain dopamine, gained nothing from tyrosine in Colzato et al. — for them it is exposure without upside, since too much dopamine impairs performance just as too little does.

  • Baseline biomarkers: A high baseline plasma tyrosine, an elevated tyrosine-to-phenylalanine ratio, or existing insulin resistance all place a person on the segment of the curve where the mortality and diabetes associations were observed, making added exposure least attractive.

  • Sex: The lifespan association in Zhao et al. reached significance in men (−0.91 years) but not women (−0.36 years). Whether this reflects a true sex difference or limited statistical power in women is unresolved.

  • Pre-existing conditions: Hyperthyroidism (an overactive thyroid), Parkinson’s disease on levodopa, malignant melanoma, bipolar disorder, schizophrenia, and the inherited disorders tyrosinemia and alkaptonuria (in which tyrosine breakdown is blocked) each convert a benign supplement into a plausible hazard.

  • Age: Adults over 60 clear tyrosine more slowly and reach higher plasma peaks on an identical per-kilogram dose, which is precisely the group in which van de Rest et al. recorded dose-dependent working-memory loss.

Key Interactions & Contraindications

  • Levodopa and carbidopa-levodopa (Sinemet, Rytary): Caution — competition for the LAT1 transporter can reduce or delay the levodopa response, producing return of tremor and rigidity. Mitigation: separating tyrosine from every levodopa dose by at least two hours, or avoiding it entirely.

  • Monoamine oxidase inhibitors (phenelzine, tranylcypromine, selegiline, rasagiline): Caution bordering on contraindication — these older antidepressants and antiparkinson drugs block catecholamine breakdown, so added precursor may drive an exaggerated blood-pressure rise. Mitigation: avoidance of the combination; where unavoidable, blood-pressure monitoring.

  • Thyroid hormone replacement (levothyroxine, liothyronine): Caution — theoretically additive thyroid stimulation. Mitigation: a thyroid-stimulating hormone recheck six to eight weeks after starting, with dosing separated by four hours since both compete for absorption.

  • Stimulants, over-the-counter decongestants and caffeine: Caution — pseudoephedrine, phenylephrine, methylphenidate, amphetamine salts and high-dose caffeine share a stimulant mechanism, so combination can produce jitteriness, a fast heart rate and raised blood pressure. Mitigation: reduction or omission of one component.

  • Supplements with additive catecholamine or thyroid effects: Caution — L-Phenylalanine and N-Acetyl-L-Tyrosine duplicate the precursor pool; Mucuna pruriens supplies levodopa; iodine, kelp and Withania somnifera act on the thyroid; synephrine and yohimbine add stimulant load. Mitigation: one at a time, never stacked.

  • Other interventions: Caution — cold exposure protocols and fasted high-intensity training already raise catecholamine output, so adding tyrosine is redundant; combined with a stimulant preworkout it is the “layering” pattern Huberman’s newsletter warns produces a trough. Mitigation: omission on those days.

Populations who should avoid L-Tyrosine:

  • People with hyperthyroidism, thyrotoxicosis (a state of excess circulating thyroid hormone) or untreated Graves’ disease (an autoimmune overactive thyroid)
  • People with a personal history of malignant melanoma at any stage
  • People taking a monoamine oxidase inhibitor, or within 14 days of stopping one
  • People with Parkinson’s disease taking levodopa, unless doses are strictly separated
  • People with bipolar disorder or a psychotic disorder, in whom dopamine-raising compounds can precipitate mania or psychosis
  • People with hereditary tyrosinemia types I, II or III, or alkaptonuria
  • Pregnant women at any supplemental dose, and breastfeeding women at doses above dietary intake
  • People with Child-Pugh Class B or C liver impairment, in whom tyrosine clearance is reduced

Risk Mitigation Strategies

  • A 500 mg starting dose rather than a research dose: Trials used 100–300 mg/kg, or 7–21 g for a 70 kg adult. Beginning at 500 mg avoids the nausea, headache and fatigue that cluster above 100 mg/kg.

  • A dose cap in adults over 60: Single doses at or below 100 mg/kg, and preferably 500–1,000 mg total, because the dose-dependent working-memory decline in older adults appeared across the 100–200 mg/kg range and tracked plasma peaks.

  • Episodic rather than daily use: Reserving tyrosine for genuinely stressful days limits cumulative exposure, which is the plausible route to the mortality and diabetes signal attached to chronically elevated circulating tyrosine.

  • Split dosing above 2 g: Taking half 60 minutes and half 30 minutes before the demand lowers peak gastric load and reduces nausea and heartburn while still elevating plasma tyrosine adequately.

  • Two hours’ separation from levodopa and four from levothyroxine: Timing separation preserves the absorption of both medicines and prevents the blunted levodopa response caused by transporter competition.

  • No dosing after 14:00: Ending dosing early in the day prevents the sleep-onset delay that a catecholamine-raising compound can cause, particularly when combined with caffeine.

  • A thyroid recheck at six to eight weeks: For anyone on thyroid hormone or with autoimmune thyroid antibodies, confirmation that thyroid-stimulating hormone has not shifted is the check before use continues beyond two months.

Therapeutic Protocol

  • Standard practitioner dose: Most clinicians and expert protocols use 500–2,000 mg of free-form L-Tyrosine on an empty stomach, taken 30–60 minutes before the cognitive or physical demand rather than on a fixed daily schedule.

  • Research dose: Trials used 100–150 mg/kg body mass, equating to 7–10.5 g for a 70 kg adult. This is far above consumer practice and is reserved for acute stress protocols, not routine use.

  • Competing approach — precursor loading versus direct dopamine supply: Huberman’s newsletter pairs 500 mg L-Tyrosine with alpha-GPC (a choline compound) before demanding work; the alternative integrative approach uses Mucuna pruriens to deliver levodopa directly, bypassing the rate-limiting enzyme.

  • Competing approach — nutritional sufficiency: Life Extension’s supplement guide argues most people need no supplement at all, since a balanced diet supplies 1–1.5 g daily and phenylalanine conversion covers the rest.

  • Best time of day: Morning to early afternoon. Effects on focus emerge 30–45 minutes after ingestion, and dosing after mid-afternoon risks delayed sleep onset.

  • Half-life: Plasma tyrosine peaks around 90–120 minutes after an oral dose and remains elevated for roughly four hours; the effective behavioural window in trials was about three hours.

  • Single versus split dosing: Single doses suffice up to about 2 g. Trials comparing one 150 mg/kg dose with two 75 mg/kg doses found the single dose raised serum tyrosine just as effectively, so splitting is a tolerability measure.

  • Genetic considerations: DRD2 C957T T/T carriers responded in the Colzato trial while C/C carriers did not; COMT Val/Val status is the analogous prefrontal marker. Neither is routinely used to select dose in practice.

  • Sex-based differences: No trial has reported a sex difference in dose–response for cognitive endpoints, and dosing protocols are identical for men and women. The only sex-specific finding concerns the lifespan association, not efficacy.

  • Age-related adjustment: Adults over 60 reach substantially higher plasma tyrosine on the same per-kilogram dose, so protocols for this group cap at the low end — 500–1,000 mg total — rather than scaling by body mass.

  • Baseline biomarkers: A normal or high fasting plasma tyrosine argues against supplementation; the depletion–repletion model predicts benefit only where availability is genuinely constrained.

  • Pre-existing conditions: Phenylketonuria dosing is set by a metabolic dietitian against blood levels, not by these protocols. Thyroid disease, Parkinson’s disease and mood disorders require the separations and cautions listed under interactions.

Discontinuation & Cycling

  • Duration of use: Short-term. Reference sources describe safety data extending to about three months at up to 150 mg/kg daily; nothing supports lifelong daily use, and the episodic, demand-linked pattern is what the trials actually tested.

  • Withdrawal effects: None documented. No trial has reported rebound symptoms, and no withdrawal syndrome has been described after stopping tyrosine at any dose studied.

  • Tapering: Not required. Because tyrosine is a dietary amino acid with no receptor occupancy and no dependence signal, abrupt discontinuation is the norm in every trial protocol.

  • Cycling: Reasonable on two grounds. The open attention-deficit trial by Reimherr et al. showed benefit fading within weeks of continuous dosing, and episodic use limits chronic exposure to elevated circulating tyrosine.

Sourcing and Quality

  • Form: Free-form L-Tyrosine powder or capsules is the form used in essentially all trials. Only the L- isomer is appropriate; D-Tyrosine impairs nutrition in mammals and does not belong in a supplement.

  • N-Acetyl-L-Tyrosine: Marketed as better absorbed, but the acetyl group must be cleaved and much is excreted unchanged in urine. Examine notes it is unclear whether it produces greater effects, so free-form remains the default.

  • Third-party testing: An NSF Certified for Sport, U.S. Pharmacopeia Verified or Informed Choice mark confirms identity, absence of heavy metals and absence of undeclared stimulants in a category prone to preworkout adulteration.

  • Manufacturing standard: A stated current Good Manufacturing Practice facility and a batch certificate of analysis showing assay purity above 98.5% — the standard specification for this amino acid — mark the better products.

  • Brands: Established amino acid suppliers with published certificates include Thorne, Pure Encapsulations, NOW Foods, Life Extension and Momentous. Compounding pharmacies are unnecessary — this is a bulk commodity amino acid, not a prescription preparation.

  • Multi-ingredient preworkouts as a source: Tyrosine in such blends is usually underdosed and bundled with stimulants, which makes both dose control and attribution of any effect impossible.

Practical Considerations

  • Time to effect: Acute. Plasma tyrosine rises within 30–45 minutes and the behavioural window closes by about three hours. There is no loading phase and no cumulative build-up to wait for.

  • Common pitfall — taking it on a good day: The entire positive literature is conditional on an imposed stressor. Taken when rested and unstressed, trials show no effect, so routine daily use mostly buys exposure without return.

  • Common pitfall — taking it with a protein meal: Competing large neutral amino acids share the same transporter, so a whey shake or steak taken alongside can cancel the dose. Trials dosed on an empty stomach.

  • Common pitfall — extrapolating research doses: The 150 mg/kg used in military trials is 10.5 g for a 70 kg adult. Consumer doses are 15–20 times smaller, and the two should not be assumed equivalent.

  • Regulatory status: Sold as a dietary supplement in the United States and the European Union, not as a medicine, so claims are unevaluated by the Food and Drug Administration. It is not on the 2026 World Anti-Doping Agency prohibited list.

  • Cost and accessibility: Inexpensive and widely available — typically under 20 US dollars for a three-month supply of 500 mg capsules. Cost is not a meaningful barrier and does not warrant further discussion here.

Interaction with Foundational Habits

  • Sleep: Potentiating in the wrong direction. Raising catecholamine tone late in the day delays sleep onset, and the effect compounds with caffeine, so no dosing after 14:00. Conversely, its clearest benefit — preserved vigilance during extended wakefulness — only matters once sleep is already lost, making it a rescue tool.

  • Nutrition: Directly antagonistic when mistimed. Protein-rich meals load the shared transporter with competing amino acids and blunt brain uptake, so tyrosine is taken fasted or with carbohydrate, which raises insulin and clears competitors. Ordinary intake from red meat, dairy, eggs, soy, nuts and hard cheese already supplies 1–1.5 g daily.

  • Exercise: Largely neutral. The pooled meta-analysis found no effect on endurance, and no evidence suggests tyrosine blunts muscle growth or interferes with training adaptation. The one positive signal is rescue of endurance under prior mental fatigue, which points to pre-session use only on cognitively depleted days.

  • Stress management: Indirect and two-edged. Tyrosine does not lower the stress response — cortisol and heart rate were unchanged in controlled stress trials — it defends performance during it, and raised self-rated anger under severe stress. It complements rather than replaces breathing, meditation and recovery practices.

Monitoring Protocol & Defining Success

Before starting, the useful baseline is narrower than for most interventions, because tyrosine is a dietary amino acid rather than a drug. A full thyroid panel is the one genuinely necessary test, since supplementation is theorised to add to thyroid hormone production and would otherwise mask or aggravate an undiagnosed problem. Seated blood pressure and resting heart rate are recorded because trials measured shifts in both under stress. Fasting glucose and glycated haemoglobin are worth capturing given the metabolic associations attached to elevated circulating tyrosine, and a plasma amino acid panel establishes whether the assumed deficit exists at all.

Ongoing monitoring is light and event-driven rather than continuous: a recheck of thyroid function and blood pressure at six to eight weeks, then every six to twelve months if use continues; fasting glucose, glycated haemoglobin and plasma tyrosine repeated annually for anyone dosing more than occasionally.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
TSH 0.5–2.0 mIU/L Detects thyroid overstimulation TSH is thyroid-stimulating hormone; mIU/L is milli-international units per litre. Conventional reference range extends to 4.5 mIU/L, which functional practitioners consider too permissive. Drawn in the morning, fasted
Free T4 1.0–1.5 ng/dL Confirms hormone output is stable T4 is thyroxine, the main hormone the thyroid releases; ng/dL is nanograms per decilitre. Paired with TSH and free T3; conventional range is 0.8–1.8 ng/dL
Free T3 3.0–4.0 pg/mL Tracks the active hormone most likely to shift T3 is triiodothyronine, the active thyroid hormone; pg/mL is picograms per millilitre. Conventional range extends down to about 2.3 pg/mL, which functional practitioners consider too permissive. Best drawn with free T4 on the same sample; biotin supplements interfere for 48 hours beforehand
TPO antibodies Negative or below assay cut-off Identifies autoimmune thyroid disease before starting TPO is thyroid peroxidase, the enzyme that attaches iodine to tyrosine inside the thyroid. A positive result is a reason to monitor more closely rather than to abandon supplementation
Plasma tyrosine (fasting) 45–90 µmol/L Establishes whether a deficit exists and whether dosing has pushed levels high µmol/L is micromoles per litre. Fasting draw required; interpreted alongside phenylalanine, since the ratio governs brain uptake
Seated blood pressure Below 120/80 mmHg Trials recorded shifts under stress, and combination with stimulants can raise it mmHg is millimetres of mercury. Measured after five minutes seated, same arm, same time of day, averaging three readings
Fasting glucose 75–86 mg/dL Anchors the metabolic risk signal tied to elevated tyrosine mg/dL is milligrams per decilitre. Conventional range extends to 99 mg/dL. Requires a 10–12 hour fast; paired with fasting insulin for greater sensitivity
HbA1c Below 5.4% Tracks the diabetes endpoint linked to circulating tyrosine HbA1c is glycated haemoglobin, a three-month average of blood sugar. Conventional cut-off is 5.7%. No fasting needed; unreliable in anaemia or recent blood loss
eGFR Above 90 mL/min/1.73 m² Screens for reduced clearance before higher-dose use eGFR is estimated glomerular filtration rate, a calculated measure of kidney filtering capacity. Rodent toxicity data implicate the kidney at extreme intakes
ALT 10–26 U/L (men), 8–22 U/L (women) Screens liver function, the site of tyrosine breakdown ALT is alanine aminotransferase, a liver enzyme released when liver cells are stressed; U/L is units per litre. Conventional upper limits near 40 U/L are considered too high functionally

Qualitative markers matter more than laboratory values here, because the intended effect is a same-session change in how work feels:

  • Subjective focus and task persistence during the 30-minute to 3-hour window after dosing, rated on a simple 1–10 scale
  • Whether the benefit appears only on stressed, cold or sleep-deprived days, which is the pattern the evidence predicts
  • Irritability or anger, the one mood change a controlled trial has isolated
  • Sleep onset latency on dosing days versus non-dosing days
  • Nausea, heartburn or headache within an hour of the dose
  • Whether the perceived effect fades over consecutive weeks of daily use, which would indicate tolerance and argue for cycling

Emerging Research

Framing note: the trials below matter to a proactive adult mainly for what they test — combination formulas at consumer doses, and the thyroid axis — rather than for population-level treatment decisions.

  • Multi-ingredient stress-and-cognition trial: NCT07319117 at Leeds Beckett University is a double-blind crossover in 40 women aged 40–60, testing a formula containing 500 mg L-Tyrosine with creatine, magnesium, L-Theanine, phosphatidylserine and citicoline against placebo, with working memory after a laboratory stressor as the primary endpoint.

  • Thyroid prevention trial: NCT06264544 is a randomised, placebo-controlled trial of 150 participants testing zinc, selenium and L-Tyrosine over six months in people carrying a variant of the selenoprotein P gene (which ferries selenium to the thyroid), with change in thyroid peroxidase antibodies as the primary outcome. It directly probes the thyroid safety question.

  • Topical tyrosine in vitiligo: NCT07742982 at Aswan University compares topical tyrosine against fluorouracil with fractional laser in 40 people with focal vitiligo (patchy loss of skin pigment), probing the melanin pathway that also underlies the melanoma concern.

  • Targeted amino acid blend in Parkinson’s disease: NCT07115563 at the University of Connecticut randomises 30 people on long-term levodopa to six months of a tyrosine-containing amino acid blend or placebo, measuring amino acid bioavailability and oxidative stress — the setting where transporter competition matters most.

  • Future direction that could strengthen the case: Whether genotype-stratified dosing reproduces the DRD2-dependent benefit seen by Colzato et al., 2016 in a preregistered replication, which would convert an inconsistent literature into a targeted one.

  • Future direction that could weaken the case: Whether repeated supplemental dosing raises time-averaged circulating tyrosine into the range associated with shorter lifespan by Zhao et al., 2025 and with diabetes by Guasch-Ferré et al., 2016. No trial has measured this, and a positive answer would undercut chronic use.

Conclusion

L-Tyrosine is a dietary amino acid that the body turns into the alertness chemicals dopamine, noradrenaline and adrenaline, and also into thyroid hormones and skin pigment. Because the body makes it from ordinary protein, most people already have enough, and the evidence follows from that fact: taking more changes little in a rested, unstressed person.

Where it does something, it does so conditionally. Trials in cold, low oxygen, loud noise and lost sleep show preserved memory and vigilance for a few hours. Older adults hold body heat better in the cold. Endurance, mood in depression, and attention deficit show either nothing or fading effects. The trials are small, the tasks differ, and no single overall figure combines them.

The safety picture is quiet in the short term and unresolved in the long term. Short courses are well tolerated; higher single doses bring stomach upset, more anger under severe stress, and, in adults over sixty, worse working memory. The unsettled question is that people with naturally higher blood tyrosine develop diabetes more often and live somewhat shorter lives — a signal from observation and genetics, never measured in supplement users.

Read together, the picture is of a compound whose demonstrated effects are narrow and conditional rather than continuous, with the thyroid, melanoma and Parkinson’s cautions attaching to particular groups rather than to everyone. The research base is thin and was built largely on military funding, and it is notably free of the commercial conflicts that shape many supplement literatures.

Top - Benefits - Risks - Protocol